Overview
This Phase 2, double-blind, placebo-controlled clinical trial assessed the short-term efficacy and safety of combining mometasone furoate nasal spray (MFNS) with oxymetazoline (OXY) for the treatment of seasonal allergic rhinitis (SAR). Over a 15-day period, 705 adolescent and adult subjects were randomized to receive either MFNS alone, OXY alone, MFNS + OXY (once or three times daily), or placebo. The study measured changes in total nasal symptom score (TNSS) and early congestion relief.
The Takeaways
-
Both MFNS + OXY combinations (1 spray or 3 sprays of OXY per nostril) significantly reduced morning/evening TNSS from baseline over 15 days compared to MFNS or OXY monotherapy or placebo (p ≤ 0.002).
-
Combination groups and MFNS alone showed significantly faster and more sustained congestion relief than placebo.
-
OXY twice daily (b.i.d.) was superior to placebo but less effective than MFNS combinations.
-
The treatment was well tolerated. Adverse events were few and similar across groups, with no treatment-related serious events.
Why It Matters
This study demonstrates that combining MFNS with oxymetazoline enhances symptom control, especially nasal congestion, in patients with seasonal allergic rhinitis—starting as early as day one. The findings support a dual-mechanism approach that combines anti-inflammatory effects of corticosteroids with the rapid vasoconstriction of decongestants for optimal relief.
The Link to Allermi
Allermi’s formulations are rooted in this exact clinical strategy—combining micro-dosed oxymetazoline with corticosteroid to achieve rapid, effective, and safe symptom relief. The study confirms that use of this combination is well-tolerated and significantly more effective than either agent alone. By personalizing dosing and delivery frequency, Allermi ensures sustained congestion relief without compromising safety, particularly during high-symptom periods like allergy season.
For more details, refer to the full study: Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis
